C-LA Europe Limited

30a Upper High Street , OX9 3EX Thame
United Kingdom

Telephone +44 1844 355472
info@claeurope.eu

This company is co-exhibitor of
Association of British Healthcare Industries Ltd.

Trade fair hall

  • Hall 16 / G25-1
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 16): stand G25-1

Fairground map

MEDICA 2016 fairground map: Hall 16

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.04  Infusion technology equipment

Infusion technology equipment

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.04  Infusion technology equipment
  • 01.03.04.20  Injection syringes

Injection syringes

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.04  Infusion technology equipment
  • 01.03.04.23  Luer syringes

Luer syringes

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.04  Infusion technology equipment
  • 01.03.04.27  Syringes
  • 05  Commodities and Consumer Goods
  • 05.08  Disposable articles for hospitals

Disposable articles for hospitals

  • 05  Commodities and Consumer Goods
  • 05.09  Disposable articles for laboratories

Disposable articles for laboratories

Our products

Product category: Infusion technology equipment, Injection syringes, Luer syringes, Syringes, Disposable articles for hospitals, Disposable articles for laboratories

Product Overview...

The CLA range of products are manufactured in our new high-technology manufacturing facility. The plant has been specifically designed for the production of medical devices in a 'clean room' environment that complies with world health regulation requirements.CLA has many benefits, some of which are...

• Provides protection from both accidental needle- sticks and re-use.
• C-LA Europe products are easy to use.
• Price advantage over other safety technologies.
• Technology is suitable for pre-filled syringes and extendable to other devices including catheters and butterflies.
• Device contains no natural rubber latex.

C-LA safety syringes will initially be offered in three commonly-used sizes. 1-ml, 3-ml and 5-ml. Other sizes will become available to meet demand at a later date. All sizes will come with a choice of high-grade needles.

More Less

About us

Company details

CLA Europe is a commercial project to produce pharmaceutical products that are in increasing, world-wide demand. The primary products are safety syringes.

‘The World Health Organization (WHO) estimates that every year unsafe injections result in 80,000-160,000 new HIV-1 infections, 8-16 million hepatitis B infections, and 2•3-4•7 million hepatitis C infections worldwide’. Source: Reeler AV. Injections: a fatal attraction. Soc Sci Med 1990; 31: 1119-25.

The global demand is of immense scope. The ramifications of not progressing to safer methods of injection are monumental: Conservative estimates suggest that in the year 2000 alone, contaminated injections caused about 260,000 new HIV infections, 21 million Hepatitis B infections and 2 million Hepatitis C infections - and recent research published in the International Journal of STD and AIDS argued that up to half of all new HIV infections may be a result of unsafe injections. Many experts agree that this problem can be solved inexpensively.

For an estimated annual cost of less than one percent of the total $15 billion HIV/AIDS package recently approved by U.S. Government, the entire continent of Africa could be supplied with safe injection devices. Doing so would effectively eliminate this entire category of disease spread, according to another WHO report.

‘There is a solution to the problem of re-used syringes, however, and that is auto-disable injection devices. These have locking features that physically prevent re-use...’ Source WHO 2000 Papers and Reports – extracts.

CLA's project has been proved viable, and has a market dimension that has yet to be quantified. It is certain, though that its position in the world market will be significant. Due to careful and methodical development and powerful inventiveness, CLA have progressed a concept through the design stages to move towards the objective: large scale manufacture, distribution and sales.

The Australian origin of the company is an advantage in several ways: technology and resources to progress the initial development of the product have been sourced close to the home base & the corporate structure (under the Australian Corporate Regulatory system (ASIC) facilitates the controlled and auditable corporate framework of a public unlisted company.

The project has been implemented, meeting objectives, and within budget parameters. CLA have now completed the second stage of the project and have developed an alliance with a reputable manufacturer of syringes located in close proximity to the European market.

Production is now underway, having the first products ready to release into the European market in the second quarter of 2013. A European marketing manager has been appointed and is establishing distributors throughout Europe to meet the high demand of good quality safety syringes that are competitive in the market.

More Less